Role of adipose-derived stem cells in enhancing angiogenesis early after aspirated fat transplantation: induction or differentiation?

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Autologous fat tissue has been used as a potential filler for soft-tissue defects, despite unpredictable clinical outcomes and low graft survival. Co-transplantation of adipose-derived stem cells (ASCs) is an alternative therapeutic approach to effectively enhance the survival and quality of transplanted fat tissue by increasing neovascularization. Nevertheless, the mechanisms by which ASCs exerted their angiogenic effects remain obscure. ASCs can secrete several angiogenic growth factors, for example vascular endothelial growth factor, hepatocyte growth factor and basic fibroblast growth factor. Hypoxic conditions may promote the proliferation of ASCs and their secretion. However, the differentiation of ASCs into endothelial cells (ECs), pericytes and smooth muscular cells in vivo has not been confirmed. The role of ASCs early after aspirated fat transplantation may be to induce new vessels from the recipient region to grow around and into the graft by releasing significant amounts of angiogenic growth factors rather than to differentiate into ECs, pericytes or smooth muscular cells forming new vessels, an effect that might be enhanced by hypoxia.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.